Sapphiros's portfolio of capabilities and technologies includes novel sample collection, next generation diagnostics, computational biology, and printed electronics
GoToKnow COVID-19 Antigen Rapid Test. (Credit: PRNewswire/Sapphiros)
Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc., formerly AmerisourceBergen Corporation.
Under the agreement, Cencora will distribute the Sapphiros GoToKnow™ COVID-19 Antigen Rapid Tests to pharmacies across the United States. This strategic partnership promises to enhance accessibility and convenience for those seeking reliable COVID-19 testing solutions nationwide.
In the future, Cencora will also have access to the future Sapphiros technologies including a fully disposable, low-cost multiplexed molecular diagnostics platform, additional rapid lateral flow tests for diseases beyond COVID-19 and the Satio™ novel blood collection patch coming in early 2024.
“This is a significant milestone for our company and further validates Sapphiros’s unique and transformational technologies,” said Mark Gladwell, CEO of Sapphiros. “We are honored to partner with Cencora to bring this product as well as future innovative product offerings directly to patients across the United States enabling the consumer to directly access their diagnostic results and manage their health.”
Source: Company Press Release